Table 2.
Included papers, clinical trial/registry/patient population characteristics
| # | Trial type | Clinical trial name | NCT number | Registry | Registry scope | Patient population | Age | Trial enrollment out of registry pre-screening | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients identified through the registry | Patients eligible for the clinical trial | Patients enrolled in the clinical trial | Enrollment rate compared to patients identified | Enrollment rate compared to patients eligible | ||||||||
| 1 | Drug trial | General eligibility for lung cancer trials and studies | N/A | Cancer registry | Local (center specific) | Patients with lung cancer | Not specified | 1 | N/A | N/A | N/A | N/A |
| 2 | Drug trial | General eligibility for cancer trials | N/A | Cancer registry | Local (center specific) | Patients with cancer | ≥ 30 | N/A | N/A | N/A | N/A | N/A |
| 3 | Non-drug trial | IMPACT | NCT03569605 | UNC Health Registry/Cancer Survivorship Cohort | Local (center specific) | Young adult cancer survivors (YACS) | 18–39 | 101 | N/A | N/A | N/A | 3.60% |
| 4 | Non-drug trial | CONTROL-RA | N/A | ArthritisPower patient registry | National | Patients with rheumatoid arthritis | ≥ 19 | 27,000 | 1254 | 234 | 0.87% | 18.60% |
| 5 | Non-drug trial | EXERT | NCT02814526 | National and local registries | Both national and local registries | Patients with mild cognitive impairment | 65–89 | N/A | N/A | N/A | N/A | N/A |
| 6 | Drug trial | 16 trials | N/A | National ALS Registry | National | Patients with amyotrophic lateral sclerosis | ≥ 18 | 7030 | N/A | 2000 | 28.40% | N/A |
| 7 | Drug trial | General eligibility for “for all available pancreatic cancer clinical trials” | N/A | Abramson Cancer Center cancer registry | Local (center specific) | Patients with pancreatic cancer | ≥ 18 | 233 | 142 | N/A | N/A | N/A |
| 8 | Drug trial | General eligibility for cancer trials | N/A | Duke Molecular Registry of Tumors | National | Patients with cancer | ≥ 18 | N/A | N/A | 32 | N/A | N/A |
| 9 | Non-drug trial | Effect evaluation of Oncokompas 2.0 | N/A | Netherlands Cancer Registry | National | Patients with cancer | ≥ 18 | 2953 | N/A | 625 | 21.20% | N/A |
| 10 | Drug trial | SHERBOC | NCT03241810 | PRAEGNANT registry | National | Postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer | ≥ 18 | 2769 | 125 | N/A | N/A | N/A |
| 11 | Non-drug trial | TARGET-AC | NCT02520180 | All comer disease registry | International | Patients with coronary artery disease | ≥ 18 | 912 | 789 | 131 | 14.40% | 16.60% |
| 12 | Non-drug trial | TASTE | NCT01093404 | Swedish Coronary Angiography and Angioplasty Registry (SCAAR) | National | Patients with a diagnosis of ST-segment elevation myocardial infarction | ≥ 18 | 11,956 | 7259 | 7244 | 60% | 99% |
| 13 | Non-drug trial | DYVINE | NCT01225614 | DM-Scope registry | National | Patients with myotonic dystrophy | ≥ 18 | 2648 | N/A | N/A | N/A | N/A |
| 14 | Drug trial | Generic eligibility for “current” pediatric type 2 diabetes | N/A | Pediatric Diabetes Consortium T2D Registry | National | Pediatric patients with diabetes | 10 to < 18 years | 956 | 604 | N/A | N/A | N/A |
| 15 | Drug trial | COMPASS | NCT01776424 | Reduction of Atherothrombosis for Continued Health (REACH) registry | International |
Coronary artery disease Patients with coronary artery disease or peripheral artery disease |
≥ 18 | 65,531 | 16,875 | 9126 | 14% | 54% |
| 16 | Drug trial | 6 trials | N/A | UK Primary Sjögren’s Syndrome Registry | National | Patients with Sjögren’s syndrome | Not specified | 688 | 681 | N/A | N/A | N/A |
| 17 | Non-drug trial | COURAGE | NCT02250053 | Pennsylvania Cancer Registry | Local (Pennsylvania) | Patients who survived colon cancer | ≥ 18 | 1435 | 1433 | 39 | 2.70% | 2.70% |
| 18 | Non-drug trial | ASCEND | NCT00135226 | Patient registry | National | Patients with diabetes | ≥ 40 | 300,188 | 16,091 | 9013 | 3% | 56% |
| 19 | Non-drug trial | COPD-SMART | NCT01108991 | Patient registry | Local (Texas) | Patients with COPD | ≥ 45 | 1666 | 924 | 325 | 19% | 35% |
| 20 | Non-drug trial | DILT1D | NCT01827735 | Patient registry | National | Patients with typ 1 Diabetes | 18–50 | 477 | 59 | 10 | 2% | 17% |
| 21 | Drug trial | OPTEX | NCT00803309 | Patient registry | National | Patients with chronic HCV | ≥ 18 | 1006 | 226 | 104 | 10% | 46% |
| 22 | Drug trial | Effect of Alfacalcidol on multiple sclerosis-related fatigue | N/A | Patient registry | Local (center specific) | Patients with MS and fatigue | 18–55 | 600 | 259 | 158 | 26% | 61% |
| 23 | Drug trial | VERVE | NCT02538341 | Consortium of Rheumatology Researchers of North America (CORRONA) disease registry | National | Patients with rheumatoid arthritis | ≥ 50 | 50,000 | 12,000 | Not indicated | N/A | N/A |
| 24 | Non-drug trial | Un-named trial | N/A | California Cancer Registry | Local and national | African American or Latino breast cancer survivors | ≥ 18 | 529 | 252 | 221 | 42% | 48% |